Gapping up
News:
- TRIP +13.2% (entered into a put option agreement to sell TheFork to American Express for $700 million in an all-cash transaction)
- CMTL +11.6% (Comtech Telecom to sell satellite business to Gilat (GILT) and refocus on public safety)
- OUST +9.3% (expands Benchmark (BHE) partnership to ramp production of Rev8 lidar sensors)
- ELTX +7.7% (reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer)
- MX +6.4% (files for $50 mln mixed securities shelf offering)
- FSM +6.4% (secures environmental approval for Diamba Sud project in Senegal)
- RYTM +6.1% (presents interim six-month data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026)
- USAR +5.9% (announces commissioning of its hydrometallurgical demonstration facility in Wheat Ridge, Colorado)
- PSKY +4.9% (DOJ approved Warner Bros. (WBD) merger on Friday)
- PGEN +4.5% (PAPZIMEOS Granted orphan drug exclusivity by FDA; long-term data from clinical study encouraging)
- CNTX +4.3% (reports interim efficacy and safety results from ongoing Phase 1 Clinical Trial for CTIM-76)
- NTLA +3.9% (reports additional Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema)
- LXEO +3.9% (Company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan intended to provide clinical evidence to support the submission of a Biologics License Application to the U.S. Food and Drug Administration for gene therapy candidate LX2006 under the accelerated approval pathway in 2028)
- ENHA +3.6% (entered into an agreement for a $50 million strategic equity financing via a private investment in public equity financing transaction)
- CLYM +3.2% (files prospectus supplement related to an open market sales agreement; may offer up to $100 mln of common stock)
- MLYS +2.8% (presents late-breaking data on Lorundrostat and heart failure risk biomarkers at The Endocrine Society Annual Meeting)
- HON +2.6% (board approves Aerospace spin-off ahead of June 29 separation)
- CRNX +2.4% (presents full results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026)
- AKAM +2% (Unveils Agentic Security Framework to Power Trusted AI-Driven Interactions and Commerce)
- PHVS +2% (reports data supporting differentiated profile of Deucrictibant in HAE Management Presented at EAACI 2026)
- FRMI +2% (files definitive consent revocation statement and mails letter to shareholders)
- GILT +1.9% (Comtech Telecom to sell satellite business to Gilat (GILT) and refocus on public safety)
- AXSM +1.9% (Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026)